Larimar Therapeutics Stock (NASDAQ:LRMR)

Forecast Ownership Financials Chart Transcripts

Previous Close

$4.77

52W Range

$1.61 - $6.42

50D Avg

$3.87

200D Avg

$3.70

Market Cap

$393.23M

Avg Vol (3M)

$4.18M

Beta

0.96

Div Yield

-

LRMR Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

65

IPO Date

Jun 19, 2014

Website

LRMR Performance

LRMR Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-90.89M	$-41.76M	$-36.53M
Net Income	$-80.60M	$-36.95M	$-34.18M
EBITDA	$-90.89M	$-41.45M	$-35.08M
Basic EPS	$-1.32	$-0.84	$-1.33
Diluted EPS	$-1.32	$-0.84	$-1.33

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 23Sep 29, 25 | 1:45 PM

Peer Comparison

Ticker	Company
ACIU	AC Immune S.A.
LXEO	Lexeo Therapeutics, Inc. Common Stock
ALT	Altimmune, Inc.
ANNX	Annexon, Inc.
ANRO	Alto Neuroscience, Inc.
KYTX	Kyverna Therapeutics, Inc.
ENGN	enGene Holdings Inc.
DBVT	DBV Technologies S.A.
AMRN	Amarin Corporation plc
KRRO	Korro Bio, Inc.